Show simple item record

dc.contributor.authorMuranen, Taru
dc.contributor.authorSelfors, Laura M.
dc.contributor.authorHwang, Julie
dc.contributor.authorGallegos, Lisa L.
dc.contributor.authorColoff, Jonathan L.
dc.contributor.authorMills, Gordon B.
dc.contributor.authorBrugge, Joan S.
dc.contributor.authorThoreen, Carson C
dc.contributor.authorKang, Seong-Cheol
dc.contributor.authorSabatini, David
dc.date.accessioned2018-07-05T13:44:25Z
dc.date.available2018-07-05T13:44:25Z
dc.date.issued2016-10
dc.date.submitted2016-09
dc.identifier.issn0008-5472
dc.identifier.issn1538-7445
dc.identifier.urihttp://hdl.handle.net/1721.1/116784
dc.description.abstractAberrant activation of the PI3K/mTOR pathway is a common feature of many cancers and an attractive target for therapy, but resistance inevitably evolves as is the case for any cancer cell-targeted therapy. In animal tumor models, chronic inhibition of PI3K/mTOR initially inhibits tumor growth, but over time, tumor cells escape inhibition. In this study, we identified a context-dependent mechanism of escape whereby tumor cells upregulated the proto-oncogene transcriptional regulators c-MYC and YAP1. This mechanism was dependent on both constitutive ERK activity as well as inhibition of the stress kinase p38. Inhibition of p38 relieved proliferation arrest and allowed upregulation of MYC and YAP through stabilization of CREB. These data provide new insights into cellular signaling mechanisms that influence resistance to PI3K/mTOR inhibitors. Furthermore, they suggest that therapies that inactivate YAP or MYC or augment p38 activity could enhance the efficacy of PI3K/mTOR inhibitors.en_US
dc.description.sponsorshipNational Institutes of Health (U.S.) (Grant R01CA103866)en_US
dc.description.sponsorshipNational Institutes of Health (U.S.) (Grant AI47389)en_US
dc.publisherAmerican Association for Cancer Research (AACR)en_US
dc.relation.isversionofhttp://dx.doi.org/10.1158/0008-5472.CAN-16-0155en_US
dc.rightsCreative Commons Attribution-Noncommercial-Share Alikeen_US
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/en_US
dc.sourcePMCen_US
dc.titleERK and p38 MAPK Activities Determine Sensitivity to PI3K/mTOR Inhibition via Regulation of MYC and YAPen_US
dc.typeArticleen_US
dc.identifier.citationMuranen, Taru et al. “ERK and P38 MAPK Activities Determine Sensitivity to PI3K/mTOR Inhibition via Regulation of MYC and YAP.” Cancer Research 76, 24 (October 2016): 7168–7180 © 2016 American Association for Cancer Research (AACR)en_US
dc.contributor.departmentMassachusetts Institute of Technology. Department of Biologyen_US
dc.contributor.departmentKoch Institute for Integrative Cancer Research at MITen_US
dc.contributor.mitauthorThoreen, Carson C
dc.contributor.mitauthorKang, Seong-Cheol
dc.contributor.mitauthorSabatini, David
dc.relation.journalCancer Researchen_US
dc.eprint.versionAuthor's final manuscripten_US
dc.type.urihttp://purl.org/eprint/type/JournalArticleen_US
eprint.statushttp://purl.org/eprint/status/PeerRevieweden_US
dc.date.updated2018-07-03T18:28:32Z
dspace.orderedauthorsMuranen, Taru; Selfors, Laura M.; Hwang, Julie; Gallegos, Lisa L.; Coloff, Jonathan L.; Thoreen, Carson C.; Kang, Seong A.; Sabatini, David M.; Mills, Gordon B.; Brugge, Joan S.en_US
dspace.embargo.termsNen_US
dc.identifier.orcidhttps://orcid.org/0000-0002-1446-7256
mit.licenseOPEN_ACCESS_POLICYen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record